June 22, 2020 / 1:20 PM / 19 days ago

BRIEF-Neoleukin Therapeutics Inc's Nl-201 Demonstrates Durable Antitumor Activity In Animal Tumor Models

June 22 (Reuters) - Neoleukin Therapeutics Inc:

* NEOLEUKIN THERAPEUTICS INC - NL-201 DEMONSTRATES DURABLE ANTITUMOR ACTIVITY IN ANIMAL TUMOR MODELS

* NEOLEUKIN THERAPEUTICS INC - NL-201 AND TARGETED VARIANTS IMPROVE OUTCOMES WHEN COMBINED WITH CAR-T CELLS IN VIVO

* NEOLEUKIN THERAPEUTICS INC - CONDITIONAL ACTIVATION OF DE NOVO PROTEINS USING SPLIT MOLECULE TECHNOLOGY MAY INCREASE THERAPEUTIC INDEX

* NEOLEUKIN THERAPEUTICS INC - MINIMAL IMMUNOGENICITY WAS REPORTED FOLLOWING FIVE WEEKLY DOSES OF NL-201 IN NON-HUMAN PRIMATES

* NEOLEUKIN THERAPEUTICS INC - TREATMENT WITH NL-201 IN ANIMAL MODELS WAS WELL-TOLERATED AND INDUCED DURABLE, ANTI-TUMOR IMMUNITY

* NEOLEUKIN THERAPEUTICS INC - NL-201 IS WELL TOLERATED AND PROMOTES DURABLE ANTI-TUMOR ACTIVITY IN PRECLINICAL MODELS

* NEOLEUKIN THERAPEUTICS INC - NL-201 DEMONSTRATES ROBUST SINGLE-AGENT ACTIVITY IN MULTIPLE TUMOR MODELS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below